Larimar’s Nomlabofusp Gains FDA Breakthrough Status, Accelerates FA Therapy Path
Event summary
- FDA grants Breakthrough Therapy Designation to nomlabofusp for Friedreich’s ataxia (FA) based on open-label study data.
- Planned Biologics License Application (BLA) submission for accelerated approval set for June 2026, with U.S. launch targeted for first-half 2027 if approved.
- FDA aligns with Larimar’s proposal to use skin FXN as a surrogate endpoint and confirms clinical outcome measures for BLA submission.
- Topline open-label study data expected in Q2 2026; global Phase 3 study initiation planned for mid-2026.
The big picture
Larimar’s Breakthrough Therapy Designation for nomlabofusp underscores the FDA’s recognition of its potential to address Friedreich’s ataxia, a rare neurodegenerative disease with limited treatment options. The strategic alignment with regulators on surrogate endpoints and clinical outcomes accelerates Larimar’s path to market, positioning it as a key player in the rare disease space. Success hinges on maintaining this regulatory momentum while executing a robust clinical and commercial strategy.
What we're watching
- Regulatory Alignment
- Whether the FDA’s acceptance of skin FXN as a surrogate endpoint will streamline Larimar’s path to approval.
- Clinical Execution
- The pace at which Larimar can initiate and complete its global Phase 3 study while preparing for BLA submission.
- Market Readiness
- How Larimar positions nomlabofusp in a competitive landscape if approved, given the high unmet need in FA treatment.
Our editorial coverage:
Related topics